[go: up one dir, main page]

WO1999065924A3 - Preparation et utilisation de vaccins superieurs - Google Patents

Preparation et utilisation de vaccins superieurs Download PDF

Info

Publication number
WO1999065924A3
WO1999065924A3 PCT/US1999/013800 US9913800W WO9965924A3 WO 1999065924 A3 WO1999065924 A3 WO 1999065924A3 US 9913800 W US9913800 W US 9913800W WO 9965924 A3 WO9965924 A3 WO 9965924A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotide
preparation
provides
complement
corresponds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/013800
Other languages
English (en)
Other versions
WO1999065924A2 (fr
Inventor
Bruce L Roberts
Srinivas Shankara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to AU52044/99A priority Critical patent/AU5204499A/en
Priority to EP99937160A priority patent/EP1086215A4/fr
Priority to CA002335452A priority patent/CA2335452A1/fr
Priority to JP2000554749A priority patent/JP2002534056A/ja
Publication of WO1999065924A2 publication Critical patent/WO1999065924A2/fr
Publication of WO1999065924A3 publication Critical patent/WO1999065924A3/fr
Anticipated expiration legal-status Critical
Priority to US10/033,145 priority patent/US20020151515A1/en
Priority to US11/332,546 priority patent/US20060134682A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention porte sur une population isolée de polynucléotides comprenant ou correspondant à au moins un polynucléotide de la Table 1 et ses compléments respectifs. L'invention porte également sur un polynucléotide codant un ligand ou un anticorps ou une protéine technique liée à une protéine de surface cellulaire d'une cellule présentatrice de l'antigène, ledit polynucléotide comprenant ou correspondant à au moins un polynucléotide de la Table 1 ou son complément. L'invention porte en outre sur un polynucléotide codant un facteur de transcription et comprenant ou correspondant à au moins un polynucléotide de la Table 1 ou son complément.
PCT/US1999/013800 1998-06-19 1999-06-18 Preparation et utilisation de vaccins superieurs Ceased WO1999065924A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU52044/99A AU5204499A (en) 1998-06-19 1999-06-18 Preparation and use of superior vaccines
EP99937160A EP1086215A4 (fr) 1998-06-19 1999-06-18 Preparation et utilisation de vaccins superieurs
CA002335452A CA2335452A1 (fr) 1998-06-19 1999-06-18 Preparation et utilisation de vaccins superieurs
JP2000554749A JP2002534056A (ja) 1998-06-19 1999-06-18 優れたワクチンの調製および使用
US10/033,145 US20020151515A1 (en) 1999-06-18 2001-11-05 Preparation and use of superior vaccines
US11/332,546 US20060134682A1 (en) 1999-06-18 2006-01-13 Preparation and use of superior vaccines

Applications Claiming Priority (58)

Application Number Priority Date Filing Date Title
US9007998P 1998-06-19 1998-06-19
US9000098P 1998-06-19 1998-06-19
US9007298P 1998-06-19 1998-06-19
US9004498P 1998-06-19 1998-06-19
US9007798P 1998-06-19 1998-06-19
US9003598P 1998-06-19 1998-06-19
US9004398P 1998-06-19 1998-06-19
US9004098P 1998-06-19 1998-06-19
US9007698P 1998-06-19 1998-06-19
US8999398P 1998-06-19 1998-06-19
US8983398P 1998-06-19 1998-06-19
US9004798P 1998-06-19 1998-06-19
US9004298P 1998-06-19 1998-06-19
US9003698P 1998-06-19 1998-06-19
US8999998P 1998-06-19 1998-06-19
US9003998P 1998-06-19 1998-06-19
US8999198P 1998-06-19 1998-06-19
US9007898P 1998-06-19 1998-06-19
US8999298P 1998-06-19 1998-06-19
US8987898P 1998-06-19 1998-06-19
US8999798P 1998-06-19 1998-06-19
US9004598P 1998-06-19 1998-06-19
US8999498P 1998-06-19 1998-06-19
US9004198P 1998-06-19 1998-06-19
US9008098P 1998-06-19 1998-06-19
US8985398P 1998-06-19 1998-06-19
US8984498P 1998-06-19 1998-06-19
US9004898P 1998-06-19 1998-06-19
US60/090,076 1998-06-19
US60/090,039 1998-06-19
US60/090,043 1998-06-19
US60/089,993 1998-06-19
US60/090,077 1998-06-19
US60/089,992 1998-06-19
US60/089,997 1998-06-19
US60/090,072 1998-06-19
US60/090,041 1998-06-19
US60/090,035 1998-06-19
US60/090,045 1998-06-19
US60/089,991 1998-06-19
US60/090,078 1998-06-19
US60/089,994 1998-06-19
US60/090,047 1998-06-19
US60/089,999 1998-06-19
US60/090,044 1998-06-19
US60/090,079 1998-06-19
US60/090,040 1998-06-19
US60/090,036 1998-06-19
US60/089,833 1998-06-19
US60/090,000 1998-06-19
US60/090,080 1998-06-19
US60/090,048 1998-06-19
US60/089,878 1998-06-19
US60/089,844 1998-06-19
US60/089,853 1998-06-19
US60/090,042 1998-06-19
US11171598P 1998-12-08 1998-12-08
US60/111,715 1998-12-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/033,145 Continuation US20020151515A1 (en) 1999-06-18 2001-11-05 Preparation and use of superior vaccines

Publications (2)

Publication Number Publication Date
WO1999065924A2 WO1999065924A2 (fr) 1999-12-23
WO1999065924A3 true WO1999065924A3 (fr) 2000-04-13

Family

ID=27586849

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013800 Ceased WO1999065924A2 (fr) 1998-06-19 1999-06-18 Preparation et utilisation de vaccins superieurs

Country Status (5)

Country Link
EP (1) EP1086215A4 (fr)
JP (1) JP2002534056A (fr)
AU (2) AU4825699A (fr)
CA (1) CA2335452A1 (fr)
WO (1) WO1999065924A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
US7041445B2 (en) * 1999-11-15 2006-05-09 Clontech Laboratories, Inc. Long oligonucleotide arrays
US20020072503A1 (en) * 2000-03-28 2002-06-13 Jiangchun Xu Compositions and methods for the therapy and diagnosis of ovarian cancer
US6632630B2 (en) 2000-03-29 2003-10-14 Aclara Biosciences, Inc. Monooxygenase assays
US7371734B2 (en) 2002-04-22 2008-05-13 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
WO2003101401A2 (fr) 2002-06-03 2003-12-11 Chiron Corporation Utilisation de nrg4, ou d'inhibiteurs de nrg4, dans le traitement du cancer du colon et du pancreas
WO2008047128A2 (fr) * 2006-10-18 2008-04-24 Nazneen Rahman Matériaux et méthodes permettant de déterminer la susceptibilité au cancer
KR20120093956A (ko) * 2009-10-12 2012-08-23 메디뮨 엘엘씨 종양 분류를 위한 ｉｒ-ａ 및 ｉｒ-ｂ의 정량
EP2322656A1 (fr) * 2009-11-17 2011-05-18 Centre National de la Recherche Scientifique (C.N.R.S) Procédés de diagnostic de maladies de la peau

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006695A1 (fr) * 1985-10-30 1989-07-27 Biogen, Inc. Dimeres clives de polypeptides semblables a substance d'inhibition mullerienne
EP0330191A2 (fr) * 1988-02-25 1989-08-30 The General Hospital Corporation ADN encodant CD40
WO1989008254A1 (fr) * 1988-03-04 1989-09-08 La Jolla Cancer Research Foundation Gene de phosphatase alcaline de cellule germinale et proteine produite par celui-ci
EP0359919A2 (fr) * 1988-06-29 1990-03-28 Ml Technology Ventures, L.P. Antigène recombinant de mycoplasma hyopneumoniae et utilisations de celui-ci
EP0363025A2 (fr) * 1988-09-30 1990-04-11 The Research Foundation for Microbial Diseases of Osaka University Peptide antigénique du virus de l'hépatite non-A, non-B
EP0362526A2 (fr) * 1988-08-23 1990-04-11 Dana Farber Cancer Institute Sous-unité du récepteur d'adhésion de leucocyte LFA-1
WO1990008160A1 (fr) * 1989-01-20 1990-07-26 Imperial Cancer Research Technology Ltd. Peptides analogues a des recepteurs de facteur de croissance ne presentant pas d'activite de tyrosine kinase
EP0431541A2 (fr) * 1989-12-08 1991-06-12 BEHRINGWERKE Aktiengesellschaft Antigène de toxoplasma gondii, sa production et son utilisation
WO1991008217A1 (fr) * 1989-12-05 1991-06-13 The Regents Of The University Of California Mucines intestinales humaines
WO1992000387A1 (fr) * 1990-06-29 1992-01-09 The Regents Of The University Of Michigan Gene de neurofibromatose

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866330A (en) * 1995-09-12 1999-02-02 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006695A1 (fr) * 1985-10-30 1989-07-27 Biogen, Inc. Dimeres clives de polypeptides semblables a substance d'inhibition mullerienne
EP0330191A2 (fr) * 1988-02-25 1989-08-30 The General Hospital Corporation ADN encodant CD40
WO1989008254A1 (fr) * 1988-03-04 1989-09-08 La Jolla Cancer Research Foundation Gene de phosphatase alcaline de cellule germinale et proteine produite par celui-ci
EP0359919A2 (fr) * 1988-06-29 1990-03-28 Ml Technology Ventures, L.P. Antigène recombinant de mycoplasma hyopneumoniae et utilisations de celui-ci
EP0362526A2 (fr) * 1988-08-23 1990-04-11 Dana Farber Cancer Institute Sous-unité du récepteur d'adhésion de leucocyte LFA-1
EP0363025A2 (fr) * 1988-09-30 1990-04-11 The Research Foundation for Microbial Diseases of Osaka University Peptide antigénique du virus de l'hépatite non-A, non-B
WO1990008160A1 (fr) * 1989-01-20 1990-07-26 Imperial Cancer Research Technology Ltd. Peptides analogues a des recepteurs de facteur de croissance ne presentant pas d'activite de tyrosine kinase
WO1991008217A1 (fr) * 1989-12-05 1991-06-13 The Regents Of The University Of California Mucines intestinales humaines
EP0431541A2 (fr) * 1989-12-08 1991-06-12 BEHRINGWERKE Aktiengesellschaft Antigène de toxoplasma gondii, sa production et son utilisation
WO1992000387A1 (fr) * 1990-06-29 1992-01-09 The Regents Of The University Of Michigan Gene de neurofibromatose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1086215A4 *

Also Published As

Publication number Publication date
AU4825699A (en) 2000-01-05
WO1999065924A2 (fr) 1999-12-23
EP1086215A2 (fr) 2001-03-28
EP1086215A4 (fr) 2005-10-19
CA2335452A1 (fr) 1999-12-23
AU5204499A (en) 2000-01-05
JP2002534056A (ja) 2002-10-15

Similar Documents

Publication Publication Date Title
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
WO2001057190A3 (fr) Acides nucleiques et polypeptides
WO2001088088A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001053312A8 (fr) Nouveaux acides nucleiques et polypeptides
WO1999020747A3 (fr) NOUVELLE KINASE HUMAINE POINT DE CONTROLE, hCDS1, COMPOSITIONS ET METHODES ASSOCIEES
WO1999065924A3 (fr) Preparation et utilisation de vaccins superieurs
AU2002364607A1 (en) Novel ligand involved in the transmigration of leukocytes .
WO2002062957A3 (fr) Compositions et methodes de biologie moleculaire
WO1998057983A3 (fr) Proteine de mammifere de type facteur de croissance nerveuse
EP0669396A4 (fr) Nouveau polypeptide et adn codant pour celui-ci.
WO2002044340A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002002625A3 (fr) Nouveaux facteurs de croissance des fibroblastes et acides nucleiques codant pour ces memes facteurs
AU2000275748A1 (en) Hla-a2.1 binding peptides and their uses
WO2000078802A3 (fr) Polypeptides secretes et polynucleotides correspondants
WO1999035263A3 (fr) Adn codant il-17rh et polypeptides il-17rh
CA2013544A1 (fr) Anticorps contre les produits de gene de retinoblastome et ses utilisations
CA2199403A1 (fr) Nouvelles proteines fixant la proteine kinase a (pka) et leur utilisation
WO2001085767A3 (fr) Nouvelles proteines humaines et polynucleotides les codant, et leur procede d'utilisation
Ahmadi The politics of ethnic nationalism in Iran.
CA2199843A1 (fr) Proteine se fixant a une kinase et ses utilisations
AU1926699A (en) Cathepsin dc proteins, dna encoding the proteins, and their use in human cancer prognosis
WO2001075093A8 (fr) Nouveaux acides nucleiques et polypeptides
WO2001087917A8 (fr) Nouveaux acides nucleiques et polypeptides
EP0927763A3 (fr) Nouvelle aroA
WO2002046417A3 (fr) Proteine associee au complement adipocyte zacrp3x2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 52044/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2335452

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 554749

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999937160

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999937160

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999937160

Country of ref document: EP